Johnson & Johnson (JNJ) Expected to Post Quarterly Sales of $20.11 Billion

Brokerages forecast that Johnson & Johnson (NYSE:JNJ) will report sales of $20.11 billion for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Johnson & Johnson’s earnings. The lowest sales estimate is $19.97 billion and the highest is $20.18 billion. Johnson & Johnson posted sales of $20.20 billion in the same quarter last year, which suggests a negative year over year growth rate of 0.4%. The firm is expected to report its next quarterly earnings results on Tuesday, January 22nd.

On average, analysts expect that Johnson & Johnson will report full year sales of $81.32 billion for the current year, with estimates ranging from $81.15 billion to $81.55 billion. For the next fiscal year, analysts forecast that the business will report sales of $82.93 billion, with estimates ranging from $81.26 billion to $85.22 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Johnson & Johnson.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.03 by $0.02. The firm had revenue of $20.35 billion for the quarter, compared to the consensus estimate of $20.05 billion. Johnson & Johnson had a return on equity of 34.97% and a net margin of 1.89%. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.90 EPS.



Several brokerages have commented on JNJ. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $160.00 price objective on shares of Johnson & Johnson in a research report on Friday, September 14th. Jefferies Financial Group set a $145.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research report on Sunday, July 15th. HC Wainwright reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Credit Suisse Group set a $149.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research report on Sunday, October 14th. Finally, ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $142.54.

Johnson & Johnson stock traded down $1.50 during mid-day trading on Friday, hitting $136.97. The company’s stock had a trading volume of 11,371,301 shares, compared to its average volume of 6,841,768. The company has a market capitalization of $371.50 billion, a PE ratio of 18.76, a price-to-earnings-growth ratio of 2.16 and a beta of 0.70. The company has a quick ratio of 1.33, a current ratio of 1.65 and a debt-to-equity ratio of 0.47. Johnson & Johnson has a one year low of $118.62 and a one year high of $148.32.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be issued a $0.90 dividend. This represents a $3.60 annualized dividend and a dividend yield of 2.63%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s dividend payout ratio is 49.32%.

In other Johnson & Johnson news, COO Michael E. Sneed sold 29,000 shares of the company’s stock in a transaction on Monday, August 27th. The stock was sold at an average price of $134.80, for a total value of $3,909,200.00. Following the completion of the sale, the chief operating officer now directly owns 59,124 shares in the company, valued at approximately $7,969,915.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Ronald A. Kapusta sold 7,899 shares of the company’s stock in a transaction on Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the sale, the chief accounting officer now owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The disclosure for this sale can be found here. 0.22% of the stock is currently owned by corporate insiders.

Several hedge funds have recently modified their holdings of JNJ. Narwhal Capital Management lifted its stake in shares of Johnson & Johnson by 2.5% during the 2nd quarter. Narwhal Capital Management now owns 40,917 shares of the company’s stock worth $4,965,000 after purchasing an additional 1,010 shares during the last quarter. TT International lifted its stake in shares of Johnson & Johnson by 254.1% during the 1st quarter. TT International now owns 136,518 shares of the company’s stock worth $15,930,000 after purchasing an additional 97,969 shares during the last quarter. Eagle Global Advisors LLC lifted its stake in shares of Johnson & Johnson by 1.6% during the 1st quarter. Eagle Global Advisors LLC now owns 77,460 shares of the company’s stock worth $9,927,000 after purchasing an additional 1,221 shares during the last quarter. Chilton Capital Management LLC lifted its stake in shares of Johnson & Johnson by 23.6% during the 1st quarter. Chilton Capital Management LLC now owns 95,055 shares of the company’s stock worth $12,181,000 after purchasing an additional 18,122 shares during the last quarter. Finally, LPL Financial LLC lifted its stake in shares of Johnson & Johnson by 9.7% during the 1st quarter. LPL Financial LLC now owns 957,508 shares of the company’s stock worth $122,705,000 after purchasing an additional 84,855 shares during the last quarter. Institutional investors and hedge funds own 66.68% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Calculate Your Return on Investment (ROI)

Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply